Bokf Na Buys 6,920 Shares of IQVIA Holdings Inc. (NYSE:IQV)

BOKF NA boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 29.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,766 shares of the medical research company's stock after purchasing an additional 6,920 shares during the period. BOKF NA's holdings in IQVIA were worth $6,254,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $33,000. GKV Capital Management Co. Inc. bought a new position in IQVIA in the fourth quarter valued at $39,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA in the 4th quarter valued at $44,000. Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in IQVIA during the 4th quarter worth about $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on IQV. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. UBS Group cut their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and cut their target price for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $231.71.

IQVIA Price Performance

Shares of IQV traded down $4.39 during mid-day trading on Friday, reaching $148.90. The company had a trading volume of 1,677,229 shares, compared to its average volume of 1,468,618. The company's 50 day simple moving average is $163.91 and its 200 day simple moving average is $188.53. The company has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter in the previous year, the firm posted $2.54 earnings per share. The company's revenue was up 2.5% on a year-over-year basis. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.